169 related articles for article (PubMed ID: 38628795)
1. Macrocyclic Oxindole Peptide Epoxyketones-A Comparative Study of Macrocyclic Inhibitors of the 20S Proteasome.
Götz MG; Godwin K; Price R; Dorn R; Merrill-Steskal G; Klemmer W; Hansen H; Produturi G; Rocha M; Palmer M; Molacek L; Strater Z; Groll M
ACS Med Chem Lett; 2024 Apr; 15(4):533-539. PubMed ID: 38628795
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome.
Wilson DL; Meininger I; Strater Z; Steiner S; Tomlin F; Wu J; Jamali H; Krappmann D; Götz MG
ACS Med Chem Lett; 2016 Mar; 7(3):250-5. PubMed ID: 26985310
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome.
Xu K; Wang K; Yang Y; Yan DA; Huang L; Chen CH; Xiao Z
Eur J Med Chem; 2015 Jun; 98():61-8. PubMed ID: 26005024
[TBL] [Abstract][Full Text] [Related]
4. TMC-95A analogues with endocyclic biphenyl ether group as proteasome inhibitors.
Kaiser M; Milbradt AG; Siciliano C; Assfalg-Machleidt I; Machleidt W; Groll M; Renner C; Moroder L
Chem Biodivers; 2004 Jan; 1(1):161-73. PubMed ID: 17191784
[TBL] [Abstract][Full Text] [Related]
5. Binding mode of TMC-95A analogues to eukaryotic 20S proteasome.
Kaiser M; Groll M; Siciliano C; Assfalg-Machleidt I; Weyher E; Kohno J; Milbradt AG; Renner C; Huber R; Moroder L
Chembiochem; 2004 Sep; 5(9):1256-66. PubMed ID: 15368577
[TBL] [Abstract][Full Text] [Related]
6. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
[TBL] [Abstract][Full Text] [Related]
7. 20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A.
Groll M; Gallastegui N; Maréchal X; Le Ravalec V; Basse N; Richy N; Genin E; Huber R; Moroder L; Vidal J; Reboud-Ravaux M
ChemMedChem; 2010 Oct; 5(10):1701-5. PubMed ID: 20715286
[No Abstract] [Full Text] [Related]
8. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
[TBL] [Abstract][Full Text] [Related]
9. Brain-Permeable Immunoproteasome-Targeting Macrocyclic Peptide Epoxyketones for Alzheimer's Disease.
Park JE; Chaudhary CL; Bhattarai D; Kim KB
J Med Chem; 2024 May; 67(9):7146-7157. PubMed ID: 38636481
[TBL] [Abstract][Full Text] [Related]
10. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities.
Koguchi Y; Kohno J; Nishio M; Takahashi K; Okuda T; Ohnuki T; Komatsubara S
J Antibiot (Tokyo); 2000 Feb; 53(2):105-9. PubMed ID: 10805568
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
[TBL] [Abstract][Full Text] [Related]
12. Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes.
Grover A; Shandilya A; Bisaria VS; Sundar D
BMC Genomics; 2010 Dec; 11 Suppl 4(Suppl 4):S15. PubMed ID: 21143798
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones.
van der Linden WA; Willems LI; Shabaneh TB; Li N; Ruben M; Florea BI; van der Marel GA; Kaiser M; Kisselev AF; Overkleeft HS
Org Biomol Chem; 2012 Jan; 10(1):181-94. PubMed ID: 22105930
[TBL] [Abstract][Full Text] [Related]
14. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome.
Groll M; Götz M; Kaiser M; Weyher E; Moroder L
Chem Biol; 2006 Jun; 13(6):607-14. PubMed ID: 16793518
[TBL] [Abstract][Full Text] [Related]
15. Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome.
Hasinoff BB
Arch Biochem Biophys; 2018 Feb; 639():52-58. PubMed ID: 29305052
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach.
Groll M; Huber R
Biochim Biophys Acta; 2004 Nov; 1695(1-3):33-44. PubMed ID: 15571807
[TBL] [Abstract][Full Text] [Related]
17. Development of a new class of proteasome inhibitors with an epoxyketone warhead: Rational hybridization of non-peptidic belactosin derivatives and peptide epoxyketones.
Kawamura S; Unno Y; Asai A; Arisawa M; Shuto S
Bioorg Med Chem; 2014 Jun; 22(12):3091-5. PubMed ID: 24814885
[TBL] [Abstract][Full Text] [Related]
18. Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome.
Groll M; Nazif T; Huber R; Bogyo M
Chem Biol; 2002 May; 9(5):655-62. PubMed ID: 12031672
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor.
Groll M; Koguchi Y; Huber R; Kohno J
J Mol Biol; 2001 Aug; 311(3):543-8. PubMed ID: 11493007
[TBL] [Abstract][Full Text] [Related]
20. Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug.
Tundo GR; Sbardella D; Oddone F; Grasso G; Marini S; Atzori MG; Santoro AM; Milardi D; Bellia F; Macari G; Graziani G; Polticelli F; Cascio P; Parravano M; Coletta M
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
